Maplight Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Catalyst4, Inc. and associated individuals have increased their beneficial ownership of MapLight Therapeutics, Inc. common stock by acquiring over 1.2 million shares in recent open market transactions.
NASDAQ
Novo Holdings A/S has reduced its stake in Maplight Therapeutics, Inc. to below 5% following a series of open market sales.
NASDAQ
Catalyst4, Inc. and its directors have reported a significant 45.1% beneficial ownership in MapLight Therapeutics, Inc. following its initial public offering and a concurrent private placement.
NASDAQ
Novo Holdings A/S has filed a Schedule 13D, revealing an 8.4% beneficial ownership stake in Maplight Therapeutics, Inc. following its recent IPO.